Transforming patient lives
through pioneering precision
Galvani Bioelectronics is a pioneering medical research company dedicated to the development of bioelectronic medicines to treat chronic diseases. Formed through a partnership between two global healthcare companies, GlaxoSmithKline (GSK) and Verily Life Sciences (formerly Google Life Sciences), a subsidiary of Alphabet Inc. Galvani Bioelectronics combines GSK’s life science knowledge with Verily’s expertise in software and electronics for clinical applications.
Galvani is developing therapies to treat disease through implant-based direct modulation of specific neural signals to organs central in chronic disease. These therapies are designed to be safe, precise in their therapeutic effect, and minimally invasive in their delivery through use of small and efficient wireless electronics and keyhole surgery. Connected software will ensure that patients and physicians can effectively control and optimise the therapy.
News & Announcements
CNN International - Saved by the Future (May 8, 2021)
TIME Magazine - Why It's Time to Take Electrified Medicine Seriously (October 24, 2019)
Medtech Strategist - Digital Taps Into Neurological Function (September 28, 2018)
publications & Presentations
A full list of scientific publications published by the Galvani Bioelectronics team can be found here: Galvani Publications
we can we do we drive
We approach work with enthusiasm, positive attitude, and a ‘glass half full’ mindset.
We pride ourselves on finding paths to the ‘yes’.
We are respectful and inclusive in interactions and always assume best intent.
We lead by example, being both leaders and individual contributors.
We support talent by rolling up our sleeves.
We believe no task is too small, no challenge too big.
We thrive on converting ideas and decisions to action.
We are proactive, next steps focused, and see out accountability.
We are tireless and ambitious.